HALO · Halozyme Therapeutics Inc
United States · RS rating 98 · As of 2026-11-03
| Price | 128.62 USD |
|---|---|
| 1-day change | -0.3% |
| RS rating (overall / 1M / 3M / 12M) | 98 / 93 / 95 / 94 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 52 / 79 / 40 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -183.9% |
| Sales growth Q/Q | +27.5% |
| Distance from 52-week high | +1.9% |
| Market cap (USD) | $7.9B |